Recent Insider Activity: Discussions on social media have recently highlighted insider buying at Entera Bio Ltd., with a notable purchase of shares by a director. This has sparked curiosity among investors about potential confidence in the company’s future. Many are debating whether this signals positive developments ahead.
Clinical Data Updates: Another focal point online is the company’s recent preclinical data on a once-daily oral treatment for hypoparathyroidism. Users are intrigued by the potential of this development, though some express caution about early-stage results. The chatter reflects a mix of optimism and skepticism as more updates are awaited.
Analyst Ratings Shift: Social media has also picked up on recent analyst downgrades for Entera Bio, with some firms suggesting a less favorable outlook. This has led to heated discussions about the stock’s current standing and future prospects. Investors appear divided on how much weight to give these ratings amidst other positive news.
Note: This discussion summary was generated from an AI condensation of post data.
Entera Bio Ltd. Insider Trading Activity
Entera Bio Ltd. insiders have traded $ENTX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ENTX stock by insiders over the last 6 months:
- MIRANDA JAYNE TOLEDANO (Chief Executive Officer) purchased 11,000 shares for an estimated $19,912
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Entera Bio Ltd. Hedge Fund Activity
We have seen 9 institutional investors add shares of Entera Bio Ltd. stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 1,518,793 shares (-56.3%) from their portfolio in Q3 2025, for an estimated $2,916,082
- MARSHALL WACE, LLP added 627,330 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,204,473
- PARKMAN HEALTHCARE PARTNERS LLC removed 75,000 shares (-21.1%) from their portfolio in Q3 2025, for an estimated $144,000
- NORTHERN TRUST CORP removed 52,077 shares (-25.9%) from their portfolio in Q3 2025, for an estimated $99,987
- HIGHTOWER ADVISORS, LLC removed 49,404 shares (-73.1%) from their portfolio in Q3 2025, for an estimated $94,855
- SCHONFELD STRATEGIC ADVISORS LLC removed 37,566 shares (-6.2%) from their portfolio in Q3 2025, for an estimated $72,126
- CITADEL ADVISORS LLC added 28,322 shares (+243.0%) to their portfolio in Q3 2025, for an estimated $54,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
